Overview

A Prospective Biomarker Study in Active SPMS Subjects Treated With Cladribine Tablets

Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore the concept that biomarker sensitivity will detect activity in Multiple Sclerosis (MS) subjects and allow appropriate change in treatment to prevent dysfunction.
Phase:
Phase 4
Details
Lead Sponsor:
Keith Edwards, M.D.
Collaborator:
EMD Serono
Treatments:
Cladribine